<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01142999</url>
  </required_header>
  <id_info>
    <org_study_id>BEEP</org_study_id>
    <nct_id>NCT01142999</nct_id>
  </id_info>
  <brief_title>Feasibility Study of Barrier Enhancement for Eczema Prevention</brief_title>
  <acronym>BEEP</acronym>
  <official_title>Feasibility Study of Barrier Enhancement for Eczema Prevention (BEEP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this protocol is to determine the feasibility of doing larger follow-up
      studies examining whether emollients used from birth can prevent eczema in high-risk babies
      and to help investigators find out if emollients (moisturizing skin creams) used from birth
      can prevent eczema in high-risk babies. Hypothesis: Enhancing the skin barrier from birth
      using emollients will prevent or delay the onset of eczema, especially in predisposed
      infants.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2010</start_date>
  <completion_date type="Anticipated">September 2012</completion_date>
  <primary_completion_date type="Anticipated">August 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of families willing to be randomized.</measure>
    <time_frame>6 months</time_frame>
    <description>Determine proportion of families willing to be randomized in order to design larger study in the future.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of families eligible for the trial, willing to participate</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of families who found the interventions acceptable</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reported adherence with intervention</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of families for whom the blinding of the assessor to the allocation ostatus was not compromised</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of contamination as a result of increased awareness in the control group</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of missing data and early withdrawal rates</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of emollient-related adverse events</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of eczema at 6 and 12 months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Age at onset of eczema</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Filaggrin mutation status</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Eczema</condition>
  <arm_group>
    <arm_group_label>Intervention (moisturizer group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One group will be instructed to use a choice of 3 FDA-approved moisturizers and soap substitutes on their newborn infants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group (no moisturizers)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will be asked NOT to use any skin moisturizers and use only soap substitutes on their infants.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunflower oil</intervention_name>
    <description>One group will be instructed to use FDA-approved moisturizers and soap substitutes on their newborn infants.</description>
    <arm_group_label>Intervention (moisturizer group)</arm_group_label>
    <other_name>Moisturizers</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control group</intervention_name>
    <description>This group will be asked NOT to use any skin moisturizers and use only soap substitutes on their infants.</description>
    <arm_group_label>Control group (no moisturizers)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aquaphor ointment</intervention_name>
    <description>One group will be instructed to use FDA-approved moisturizers and soap substitutes on their newborn infants.</description>
    <arm_group_label>Intervention (moisturizer group)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetaphil cream</intervention_name>
    <description>One group will be instructed to use FDA-approved moisturizers and soap substitutes on their newborn infants.</description>
    <arm_group_label>Intervention (moisturizer group)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participant must have a parent or sibling with a history of at least one of the
             following: eczema, allergic rhinitis or asthma

          2. Infant in overall good health

          3. Mother between the ages of 16 and 45 years of age at delivery; infant from birth thru
             6 months of age

          4. Capable of giving informed consent

        Exclusion Criteria:

          1. Preterm birth defined as birth prior to 37 weeks gestation

          2. Major congenital anomaly

          3. Hydrops fetalis

          4. Significant dermatitis at birth not including seborrheic dermatitis (&quot;cradle cap&quot;)

          5. Any immunodeficiency disorder or severe genetic skin disorder

          6. Any other serious condition that would make the use of emollients inadvisable

          7. Any other major medical problems that the investigator deems may increase the risk of
             adverse events with the intervention
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric L. Simpson, M.D., M.C.R.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2010</study_first_submitted>
  <study_first_submitted_qc>June 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2010</study_first_posted>
  <last_update_submitted>August 4, 2011</last_update_submitted>
  <last_update_submitted_qc>August 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2011</last_update_posted>
  <responsible_party>
    <name_title>Eric L. Simpson, M.D., M.C.R.</name_title>
    <organization>Oregon Health &amp; Science University</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

